NDA 016750 · Amphastar Pharms INC
Cortrosyn
Cosyntropin · Injection · Adrenocorticotropic Hormone
NovelLast checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1970
Apr 22, 1970
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
3 Phase 3, 2 recruiting
FAERS reports
220
188 serious, 27 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2026.
CORTROSYN is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. CORTROSYN is an adrenocorticotropin hormone indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 22, 1970 Original approval · Type 1 - New Molecular Entity
1 products under this application
- CORTROSYN · COSYNTROPIN 0.25MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cosyntropin" as an intervention, any sponsor and status, largest first.
- A Novel Approach to Infantile SpasmsPivotal-lookingSuspended
University of Colorado, DenverAcademic, hospital or other
NCT03347526 · 394 participants (planned) · Start Apr 19, 2018 · Primary completion Jun 2021
Drug: Cosyntropin Injectable Suspension, 1 mg/mL; Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin and 1 more · For: Infantile Spasm
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 14 sites in all
University of MichiganAcademic, hospital or other
NCT01673087 · 256 participants · Start Oct 2012 · Primary completion Aug 15, 2017
Drug: Metyrapone; Dexamethasone and 2 more · For: Stress
Sites: Ann Arbor, Michigan
Haukeland University HospitalAcademic, hospital or other
NCT02818660 · 232 participants · Start May 21, 2016 · Primary completion Dec 21, 2017
Drug: Synachten · For: Adrenal Insufficiency
Sites: Bergen, Norway
- Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA)Pivotal-lookingCompleted
Chongqing Medical UniversityAcademic, hospital or other
NCT04461535 · 228 participants · Start Jul 8, 2020 · Primary completion Feb 20, 2023
Drug: Adrenocorticotropic hormone · For: Primary Aldosteronism
Sites: Chongqing, China
Cardiff UniversityAcademic, hospital or other
NCT00851942 · 165 participants · Start Sep 2008 · Primary completion Jul 28, 2012
Drug: Synacthen (Tetracosactrin) · For: Healthy; Adrenal Insufficiency; Hypopituitarism
Sites: Cardiff, United Kingdom
- Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOSStatus unknown
University of VirginiaAcademic, hospital or other
NCT03905603 · 144 participants (planned) · Start Oct 8, 2019 · Primary completion Apr 1, 2026
Drug: ACTH; rhCG · For: Polycystic Ovary Syndrome
Sites: Charlottesville, Virginia
- Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac SurgeryPivotal-lookingCompleted
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT00415701 · 130 participants (planned) · Start Nov 2006 · Primary completion Dec 2009
Drug: Etomidate; Propofol and 2 more · For: Coronary Artery Disease; Mitral Valve Regurgitation
Sites: Bern, Switzerland
- Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?Pivotal-lookingCompleted
University of VirginiaAcademic, hospital or other
NCT03368066 · 100 participants · Start Jan 29, 2018 · Primary completion Mar 12, 2019
Drug: Cosyntropin · For: Adrenal Insufficiency; Cirrhosis; Spur Cell Anemia and 1 more
Sites: Charlottesville, Virginia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal growth restriction24
- foetal exposure during pregnancy23
- hypoglycaemia20
- hypotension18
- dyspnoea13
- pneumonia13
- nausea12
- hyperkalaemia11
- sepsis11
- adrenal insufficiency10
- rash10
- dizziness8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 12 |
| 2013 | 6 |
| 2014 | 9 |
| 2015 | 5 |
| 2016 | 13 |
| 2017 | 1 |
| 2018 | 10 |
| 2019 | 19 |
| 2020 | 14 |
| 2021 | 23 |
| 2022 | 15 |
| 2023 | 14 |
| 2024 | 10 |
| 2025 | 15 |
| 2026 | 13 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Cortrosyn* (Cosyntropin*) · HCPCS J0834
2024 spending
$76K
Beneficiaries
2,826
3,012 claims
Per beneficiary
$27
2024 ASP limit $25.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $127,878 |
| 2021 | $105,648 |
| 2022 | $93,733 |
| 2023 | $83,873 |
| 2024 | $75,645 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.
Carmina E, Dewailly D, Escobar-Morreale HF, et al. · Hum Reprod Update 2017 · Meta-Analysis, Systematic Review
- First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.
Shimizu H, Tortorici MA, Ohta Y, et al. · Clin Transl Sci 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
- Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.
Annane D, Pastores SM, Rochwerg B, et al. · Intensive Care Med 2017 · Consensus Statement, Practice Guideline
- Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone.
Bhatia N, Eichenfield LF, Mazzetti A, et al. · J Drugs Dermatol 2024 · Multicenter Study, Clinical Trial, Phase II
- Residual Corticosteroid Production in Autoimmune Addison Disease.
Sævik ÅB, Åkerman AK, Methlie P, et al. · J Clin Endocrinol Metab 2020 · Clinical Trial, Multicenter Study
- Is Inappropriate Response to Cosyntropin Stimulation Test an Indication of Corticosteroid Resistance in Septic Shock?
Hyvernat H, Doyen D, Barel R, et al. · Shock 2018 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Amphastar Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.